CLAIMS

1. A compound of the formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B independently represent CH_2 or O, with the proviso that A and B are not simultaneously O;

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}haloalkyl, C_{1-6}alkylamino and amino;

R^1 and R^2 are independently selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}haloalkyl and C_{3-8} cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or C_{1-6} alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy and C_{1-6}haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N,

when p represents 2 or more, two of R^2s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring.

2. A compound according to claim 1 where A and B represent carbon atoms.

3. A compound according to claim 1 where A represents O and B represents C.

4. A compound according to claim 1 where A represents C and B represents O.

5. A compound according to any one of claims 1 to 4 where Cy is selected from optionally further substituted 4-hydroxyphenyl, 1*H*-pyrazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazole-6-yl and 2-hydroxy-5-pyridyl.

6. A compound according to any one of claims 1 to 5 where Cy represents 4-hydroxyphenyl, optionally further substituted by fluoro or methyl.

7. A compound according to any one of claims 1 to 6 where n represents 0.

8. A compound according to any one of claims 1 to 7 where R^2 represents methoxy, chloro, fluoro or methyl.

9. A compound according to any one of claims 1 to 8 where p represents 0-2.

10. A compound according to any one of claims 1 to 9 where X is hydrogen or hydroxy.

11. A compound according to any one of claims 1 to 10 where Y is selected from methylene, oxyethyleneoxy, oxymethylene, methyleneoxy, methyleneoxymethylene, ethyleneoxy, oxyethylene and oxy.

12. A compound according to any one of claims 1 to 11 where Y is *para* located to and in a *trans* configuration to X.

13. A compound of formula (I) selected from:

4-Hydroxy-*N*-{[*cis*-4-(phenoxymethyl)cyclohexyl]methyl}benzamide;

4-Hydroxy-*N*-({*cis*-4-[(4-methoxyphenoxy)methyl]cyclohexyl}methyl)benzamide;

N-{[*cis*-4-(Benzyloxy)cyclohexyl]methyl}-4-hydroxybenzamide;

N-({*cis*-4-[(4-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;

N-({*cis*-4-[(3-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;

4-Hydroxy-*N*-{[*cis*-4-(4-methoxyphenoxy)cyclohexyl]methyl}benzamide;

N-{[*cis*-4-(4-Chlorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;

4-Hydroxy-*N*-{[1-hydroxy-4-(phenoxymethyl)cyclohexyl]methyl}benzamide;

N-({*trans*-4-[(4-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(3-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(2-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(2,6-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(3,5-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(3-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[(4-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(2-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(3-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(4-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

N-({*trans*-4-[(Benzyloxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-[(*trans*-4-{[(2-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

N-[(*trans*-4-{[(4-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

4-Hydroxy-*N*-{[*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl]methyl}benzamide;

N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[2-(3-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[2-(4-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-{[*trans*-4-(Benzyloxy)-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;

N-{[*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;

N-{[*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;

N-{[*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;

N-{[*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;

(+)-4-hydroxy-*N*-{[5*S*-(phenoxymethyl)tetrahydro-2*H*-pyran-2*S*-yl]methyl}benzamide;

(-)-4-hydroxy-*N*-{[5*R*-(phenoxymethyl)tetrahydro-2*H*-pyran-2*R*-yl]methyl}benzamide;

4-hydroxy-*N*-{[5*S*-(benzyloxymethyl)tetrahydro-2*H*-pyran-2*S*-yl]methyl}benzamide;

4-hydroxy-*N*-{[5*R*-(benzyloxymethyl)tetrahydro-2*H*-pyran-2*R*-yl]methyl}benzamide;

(-)-4-Hydroxy-*N*-{[(3*R*,6*S*)-6-(phenoxymethyl)tetrahydro-2*H*-pyran-3-yl]methyl}benzamide;

(+)-4-Hydroxy-*N*-{[(3*S*,6*R*)-6-(phenoxymethyl)tetrahydro-2*H*-pyran-3-yl]methyl}benzamide;

N-({*trans*-4-[(2-Fluorobenzyl)oxy]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

3-Fluoro-*N*-({*trans*-4-[2-(2-fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

trans -*N*-{[4-(4-chlorophenoxy)cyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;

cis- *N*-{[4-(4-chlorophenoxy)cyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;

N-{[*cis*-4-(4-Fluorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;

3-Fluoro-*N*-{[*cis*-4-(4-fluorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;

N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-1*H*-pyrazole-4-carboxamide;

4-hydroxy-*N*-{[*cis*-4-(2-phenylethoxy)cyclohexyl]methyl}benzamide;

2-fluoro-4-hydroxy-*N*-{[*trans*-1-hydroxy-4-(phenoxymethyl)cyclohexyl]methyl}benzamide;

N-({*trans*-4-[(benzyloxy)methyl]-1-hydroxycyclohexyl}methyl)-3-fluoro-4-hydoxybenzamide;

N-({*cis*-4-[(Benzyloxy)methyl]cyclohexyl}methyl)-4-hydroxybenzamide

3-Fluoro-4-hydroxy-*N*-{[*trans*-1-hydroxy-4-(phenoxymethyl)cyclohexyl]methyl}benzamide;

3-Fluoro-4-hydroxy-*N*-{[*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl]methyl}benzamide;

3-Fluoro-*N*-[(*trans*-4-{[(4-fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

3-Fluoro-*N*-({*trans*-4-[(2-fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

3-Fluoro-*N*-({*trans*-4-[(4-fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

4-Hydroxy-*N*-[(*trans*-1-hydroxy-4-{[(5-methylpyridin-2-yl)oxy]methyl}cyclohexyl)methyl]benzamide;

N-[(*trans*-4-Benzyl-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

3-fluoro-*N*-[(*trans*-4-{[(2-fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

6-Hydroxy-*N*-{[*cis*-4-(2-phenethoxy)cyclohexyl]methyl}nicotinamide;

N-{[*cis*-4-(2-Phenylethoxy)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;

N-{[*cis*-4-(Phenoxymethyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;

N-{[*cis*-4-(2-Phenoxyethyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;

N-({*cis*-4-[(3-Fluorophenoxy)methyl]cyclohexyl}methyl)-1*H*-pyrazole-4-carboxamide;

N-({*cis*-4-[(4-Fluorophenoxy)methyl]cyclohexyl}methyl)-1*H*-pyrazole-4-carboxamide;

N-({(2*R*,5*R*)-5-[(4-Fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl}methyl)-1*H*-pyrazole-4-carboxamide;

N-{[*cis*-4-(4-Methoxybenzyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;

3-Amino-*N*-[(*cis*-4-benzylcyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;

N-({(2*R*,5*R*)-5-[(4-Chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl}methyl)-1*H*-pyrazole-4-carboxamide;

3-Amino-*N*-({(2*R*,5*R*)-5-[(4-fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl}methyl)-1*H*-pyrazole-4-carboxamide;

3-Amino-*N*-({(2R,5R)-5-[(4-chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl}methyl)-1*H*-pyrazole-4-carboxamide; and

3-Amino-*N*-({(2*R*,5*R*)-5-[(4-ethylphenoxy)methyl]tetrahydro-2*H*-pyran-2-yl}methyl)-1*H*-pyrazole-4-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

14. A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 13, together with a pharmaceutically acceptable excipient.

15. A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 14, for use as a medicament.

16. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1 to 13 and 14, respectively, for the manufacture of a medicament to treat a disease for which an NMDA NR2B antagonist is indicated.

17. A use according to claim 16 where the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.

18. A method of treatment of a mammal, including a human being, to treat a disease for which an NMDA NR2B antagonist is indicated, including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1 to 13 and 14, respectively.

19. A method according to claim 18 where the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.

20. A combination of a compound of the formula (I), as defined in any one of claims 1-13, and another pharmacologically active agent.